Zura Bio Reports Second Quarter 2023 Financial Results and R

Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa



Experienced team building the next immunology...
-Today at 07:01 am- MarketScreener

Related Keywords

, Eli Lilly , Zura Bio , Michaeld Howell , Someit Sidhu , Company Press , Head Of Translational Science Press , Indexes Press , Zura Bio Limited Nasdaq , Zura Bio Limited , Chief Executive Officer , Press Release , Deep Track Capital , Great Point Partners , Suvretta Capital , Chief Scientific Officer , Translational Science , Initiate Phase , Inflammation Virtual Summit , Annual Inflammation , Immunology Conference , Private Securities Litigation Reform Act , Convertible Preferred Shares , Redeemable Noncontrolling Interest , Shareholder Equity , Consolidated Statements , Three Months , Ordinary Shareholders , Ordinary Shares , Markets ,